Latest news with #GeneDx.com
Yahoo
22-05-2025
- Business
- Yahoo
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 22, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Jefferies Global Healthcare Conference – June 4, 2025New York City, New YorkFireside chat on Wednesday, June 4 at 9:55 a.m. ET Goldman Sachs 46th Annual Global Healthcare Conference – June 9, 2025Miami Beach, FloridaFireside chat on Monday, June 9 at 4:00 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at About GeneDxAt GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook, and Instagram. View source version on Contacts Investor Relations Contact: Investors@ Media Contact: Press@
Yahoo
20-03-2025
- Business
- Yahoo
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., March 20, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15, 2025, the compensation committee of GeneDx's board of directors granted 46,340 restricted stock units ("RSUs") to ten newly-hired employees as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over a four-year period, subject to the employee's continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, X, Facebook, and Instagram. View source version on Contacts Investor Relations:Investors@ Media:Press@
Yahoo
12-02-2025
- Business
- Yahoo
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
GAITHERSBURG, Md., February 12, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA. Management will participate in a fireside chat on Tuesday, March 4, 2025, at 1:10 p.m. ET. A live and archived webcast of the presentation will be available on the "Events" section of the GeneDx investor relations website at About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook, and Instagram. View source version on Contacts Investor Relations: Investors@ Media: Press@ Sign in to access your portfolio
